Author

B. Manning

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:clustering· 1

Frequent Co-Authors

G. Wertheim· 2 shared M. Carroll· 2 shared A. Bakayoko· 1 shared A. Bigdeli· 1 shared A. D'Alessandro· 1 shared A. Kossenkov· 1 shared A. Lehman· 1 shared A. Lenard· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Wertheim

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Intraperitoneal activation of myeloid cells clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer

N. Zhang, B. Murphy, T. Miyamoto, B. Manning, G. Mirji, A. Ugolini, T. Kannan, K. Hamada, Y. Zhu, D. Claiborne, L. Huang, R. Zhang, Y. Nefadova, A. Kossenkov, F. Veglia, R. Shinde

The paper shows that intraperitoneal administration of β-glucan and IFNγ clears ascites and induces IL27-dependent tumor regression in metastatic ovarian cancer models.

bioRxiv · Jun 25, 2024 · PreprintImmunology

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

S. J. Skuli, A. Bakayoko, M. Kruidenier, B. Manning, P. Pammer, A. Salimov, O. Riley, G. Brake-Silla, M. Bowman, L. N. Martinez-Gutierrez, R. Buono, M. Paul, E. Saland, S. Wong, J. Xu, , M. Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

bioRxiv · Jun 7, 2024 · PreprintCancer Biology

Clonal evolution mediates Menin-inhibitor resistance in KMT2A-rearranged leukemias.

L. Mahdavi, H. Goodrow, F. Alikarami, A. Lenard, S. S. Riedel, C. Libbrecht, I. Bowser, S. K. Tasian, C. Falkenstein, B. Manning, S. Skuli, M. P. Carroll, G. Wertheim, S. Cai, G. McGeehan, , K. M. Bernt

This study shows that Menin-inhibitor resistance in KMT2A-rearranged leukemias arises through clonal evolution, with resistance developing without prior exposure to the inhibitor.

bioRxiv · Mar 16, 2023Cancer Biology

Classes of ITD predict outcomes in patients with AML treated with FLT3 inhibitors

G. W. Schwartz, B. Manning, Y. Zhou, P. Velu, A. Bigdeli, R. Astles, A. Lehman, J. Morrissette, A. Perl, M. Carroll, R. Faryabi

The paper classifies FLT3-ITD mutations into typical and atypical based on nucleotide composition and shows typical ITD carriers have better outcomes with FLT3 inhibitors.

bioRxiv · May 14, 2018Cancer Biology